In a groundbreaking development for cancer immunotherapy, Evaxion A/S, a clinical-stage TechBio company based in Copenhagen, is set to present two-year clinical efficacy data from its phase 2 trial with the AI-designed personalized cancer vaccine, EVX-01. The presentation will take place at the prestigious European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, from October 17-21, 2025, marking a significant milestone for the company and its innovative treatment options.

Evaxion, known for its pioneering AI-Immunology™ platform, has developed EVX-01 as a personalized cancer vaccine specifically targeting patients with advanced melanoma. This therapy employs artificial intelligence to analyze individual biological data, enabling the customization of vaccine formulations that more effectively trigger a robust immune response against cancer cells. The ongoing phase 2 trial investigates EVX-01 in synergy with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), opening new avenues for enhanced treatment efficacy in melanoma patients.

The efficacy of EVX-01 is underscored by the significant findings shared during the interim analysis presented at the ESMO Congress in September 2024, which reported a remarkable 69% Overall Response Rate. The data showed positive outcomes, with a reduction in tumor target lesions observed in 15 out of 16 patients. Additionally, there was a compelling correlation between the predictions made by the AI-Immunology™ platform and the immune responses triggered by the individual neoantigens inherent to the vaccine, demonstrating a highly promising avenue in personalized medicine (p=0.00013).

As anticipation builds for the full two-year data report, Evaxion’s Chief Scientific Officer and interim CEO, Birgitte Rønø, expressed excitement over the opportunity to present these findings at one of the most influential gatherings in the medical oncology field. The ESMO Congress attracts a diverse audience, including researchers, oncologists, and potential partners, providing an ideal platform for Evaxion to showcase their breakthrough innovation and seek further collaboration and investment opportunities.

Details surrounding the presentation include an abstract entitled, “EVX-01, a personalized cancer vaccine, induces potent T-cell responses and durable disease control in advanced melanoma: 2-year follow-up,” which has been allocated the identifier #6308 for the congress. The presentation will be delivered by Dr. Muhammad Adnan Khattak, a leader in oncology research from One Clinical Research, with a focus on the investigational immunotherapy track. It is scheduled for October 17, 2025, at 14:10 – 14:15 CEST in the Nuremberg Auditorium – Hall 5.2.

EVX-01 represents Evaxion’s most advanced clinical asset and is designed not only for patients with melanoma but aims to establish efficacy across multiple advanced solid tumors. The personalized nature of EVX-01 allows each patient to receive a unique vaccine tailored to their specific tumor profile and immune characteristics, encouraging a targeted immune response against cancer. This innovative approach can change the paradigm of cancer treatment, allowing for higher levels of customization in patient care.

The recently completed phase 1/2a clinical trial (NCT03715985) demonstrated considerable promise, as 67% of patients with metastatic melanoma showed objective clinical responses, including two complete and six partial responses. With such encouraging results, the medical community remains hopeful that therapies like EVX-01 could redefine treatment standards for cancer patients, paving the way for more personalized and effective immunotherapy solutions.

As the wave of AI and immunotherapy continues to revolutionize the landscape of cancer treatment, Evaxion’s upcoming presentation at the ESMO Congress 2025 will not only reflect on the progress achieved with EVX-01 but will also capture the attention of business leaders, investors, and oncology experts eager to explore the future of personalized medicine.